Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- October 31, 2008
- Published online March 13, 2009.
Article Versions
- Latest version (February 17, 2009 - 12:45).
- You are viewing the most recent version of this article.
Copyright & Usage
Author Information
- EDWARD KEYSTONE,
- BRUCE FREUNDLICH,
- MICHAEL SCHIFF,
- JUAN LI and
- MICHELE HOOPER
- From Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; Wyeth Research, Collegeville, Pennsylvania; University of Colorado, Denver, Colorado; and Amgen Inc., Thousand Oaks, California, USA
- E. Keystone has conducted research, served on consultant/advisory boards, and/or participated as a speaker for Abbott Laboratories, Amgen, Aventis Pharma, Bristol-Myers Squibb, Celltech, Centocor, CombinatoRx, Genentech, Hoffman-La Roche Ltd (Canada), Novartis, Schering Plough, Targeted Genetics, Therakos, and Wyeth Research. M. Schiff has conducted research, served as a consultant, and/or participated as a speaker for Abbott Laboratories, Amgen, Bristol-Myers Squibb, Centocor, Genentech, Roche, UCB, Targeted Therapies, and Wyeth Research. B. Freundlich is an employee of Wyeth Research. M. Hooper and J. Li are employees of Amgen.
- E. Keystone, MD, FRCPC, Mount Sinai Hospital, University of Toronto, Toronto, ON; B. Freundlich, MD, Wyeth Research, Collegeville, PA; M. Schiff, MD, University of Colorado, Denver, CO; J. Li, PhD; M. Hooper, MD, Amgen Inc., Thousand Oaks, CA.
- Address reprint requests to Dr. E. Keystone, Mount Sinai Hospital, The Rebecca MacDonald Centre for Arthritis and Autoimmunity, 60 Murray St., Room 2–006, Toronto, ON M5G 1X5, Canada. E-mail: edkeystone{at}mtsinai.on.ca
Article usage
Statistics from Altmetric.com
In this issue
Patients with Moderate Rheumatoid Arthritis (RA) Achieve Better Disease Activity States with Etanercept Treatment Than Patients with Severe RA
